Background: There has been poor translation for the use of immunosuppressive agents from experimental autoimmune encephalomyelitis (EAE), an animal model of multiple sclerosis (MS), into the treatment of MS. This may be due to the fact that most EAE studies examine prophylactic, pre-treatment regimes that prove to be therapeutically-ineffective in long-established, often progressive, MS. FTY720 (fingolimod/Gilenya) is a sphingosine-1-phosphate receptor modulator. This is a new oral agent that markedly reduces the number of relapses in people with MS, compared with currently licensed injectable agents such as the beta interferons. FTY720 has activity against lymphocytes but may also influence oligodendroglia and could therefore have the potential to influence progressive MS, by promoting remyelination.
Methods: The effect of FTY720 was assessed in relapsing-progressive EAE in mice.
Results: Early intervention during relapsing EAE could completely inhibit subsequent relapses, inhibited the accumulation of neurodegeneration, and facilitated motor recovery. However, when examined in secondary progressive EAE, that develops after the accumulation of deficit from relapsing disease, long-term treatment with FTY720 failed to slow deterioration when initiated late (4 months) into the disease course.
Conclusions: This study indicates that early intervention with immunosuppressive agents may inhibit the generation of the neurodegenerative microenvironment, which is no longer responsive to potent immunosuppression. However, if treatment is initiated too late, progressive, neurological-disease continues unabated. This suggests that immunosuppression is insufficient to control secondary progression in animals, as has been found so far to be the case in MS, and may warrant early intervention with FTY720 for optimal treatment benefit.
PolmanCHO'ConnorPWHavrdovaE. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med2006; 354: 899–910.
4.
YednockTACannonCFritzLCSanchez-MadridFSteinmanLKarinN. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–66.
5.
BrennanFRO'NeillJKAllenSJButterCNukiGBakerD. CD44 is involved in selective leucocyte extravasation during inflammatory central nervous system disease. Immunology1999; 98: 427–435.
6.
BjartmarCTrappBD. Axonal degeneration and progressive neurologic disability in multiple sclerosis. Neurotox Res2003; 5: 157–164.
7.
BjartmarCWujekJRTrappBD. Axonal loss in the pathology of MS: consequences for understanding the progressive phase of the disease. J Neurol Sci2003; 206: 165–171.
8.
BillichABornancinFDevayPMechtcheriakovaDUrtzNBaumrukerT. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J Biol Chem2003; 278: 47408–47415.
PinschewerDDOchsenbeinAFOdermattBBrinkmannVHengartnerHZinkernagelRM. FTY720 immunosuppression impairs effector T cell peripheral homing without affecting induction, expansion, and memory. J Immunol2000; 164: 5761–5770.
11.
MatloubianMLoCGCinamonG. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature2004; 427: 355–360.
12.
KapposLAntelJComiG. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med2006; 355: 1124–1140.
13.
O'ConnorPComiGMontalbanX. Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology2009; 72: 73–79.
14.
Cohen J, Pelletier J, Kappos L et al. Oral Fingolimod (FTY720) Versus Interferon Beta-1a in Relapsing Remitting Multiple Sclerosis: Results from a Phase III Study (TRANSFORMS). Slide deck associated with Oral Presentation at the American Academy of Neurology Annual Meeting 2009, S21.004.
15.
CohenJABarkhofFComiG. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med2010; 362: 402–415.
16.
KapposLRadueEWO'ConnorP. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med2010; 362: 387–401.
17.
FujinoMFuneshimaNKitazawaY. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther2003; 305: 70–77.
KataokaHSugaharaKShimanoK. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell Mol Immunol2005; 2: 439–448.
20.
BalatoniBStorchMKSwobodaEM. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis. Brain Res Bull2007; 74: 307–316.
21.
SanchezTHlaT. Structural and functional characteriztics of S1P receptors. J Cell Biochem2004; 92: 913–922.
22.
FosterCAHowardLMSchweitzerA. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis. J Pharmacol Exp Ther2007; 323: 469–475.
23.
OsindeMMullershausenFDevKK. Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes via S1P receptors. Neuropharmacology2007; 52: 1210–1218.
BrinkmannV. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol2009; 158: 1173–1182.
26.
MironVEJungCGKimHJKennedyTESolivenBAntelJP. FTY720 modulates human oligodendrocyte progenitor process extension and survival. Ann Neurol2008; 63: 61–71.
27.
CoelhoRPPayneSGBittmanRSpiegelSSato-BigbeeC. The immunomodulator FTY720 has a direct cytoprotective effect in oligodendrocyte progenitors. J Pharmacol Exp Ther2007; 323: 626–635.
28.
JungCGKimHJMironVE. Functional consequences of S1P receptor modulation in rat oligodendroglial lineage cells. Glia2007; 55: 1656–1667.
29.
HamptonDWAndersonJPryceG. An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss. J Neuroimmunol2008; 201: 200–211.
30.
PryceGO'NeillJKCroxfordJL. Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis. J Neuroimmunol2005; 165: 41–52.
31.
BakerDO'NeillJKGschmeissnerSEWilcoxCEButterCTurkJL. Induction of chronic relapsing experimental allergic encephalomyelitis in Biozzi mice. J Neuroimmunol1990; 28: 261–270.
32.
O'NeillJKButterCBakerD. Expression of vascular addressins and ICAM-1 by endothelial cells in the spinal cord during chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. Immunology1991; 72: 520–525.
33.
O'NeillJKBakerDDavisonAN. Control of immune-mediated disease of the central nervous system with monoclonal (CD4-specific) antibodies. J Neuroimmunol1993; 45: 1–14.
34.
O'NeillJKBakerDTurkJL. Inhibition of chronic relapsing experimental allergic encephalomyelitis in the Biozzi AB/H mouse. J Neuroimmunol1992; 41: 177–187.
35.
BakerDPryceGCroxfordJL. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature2000; 404: 84–87.
36.
BakerDPryceGCroxfordJL. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J2001; 15: 300–302.
37.
JacksonSJLeeJNikodemovaMFabryZDuncanID. Quantification of myelin and axon pathology during relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. J Neuropathol Exp Neurol2009; 68: 616–625.
38.
JacksonSJPryceGDiemelLTCuznerMLBakerD. Cannabinoid-receptor 1 null mice are susceptible to neurofilament damage and caspase 3 activation. Neuroscience2005; 134: 261–268.
39.
O'NeillJKBakerDDavisonANMaggonKKJaffeeBDTurkJL. Therapy of chronic relapsing experimental allergic encephalomyelitis and the role of the blood–brain barrier: elucidation by the action of Brequinar sodium. J Neuroimmunol1992; 38: 53–62.
40.
PryceGAhmedZHankeyDJ. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain2003; 126: 2191–2202.
41.
MandalaSHajduRBergstromJ. Alteration of lymphocyte trafficking by sphingosine-1-phosphate receptor agonists. Science2002; 296: 346–349.
42.
FosterCAMechtcheriakovaDStorchMK. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood–brain-barrier damage. Brain Pathol2009; 19: 254–266.
43.
KanwarJRKanwarRKKrissansenGW. Simultaneous neuroprotection and blockade of inflammation reverses autoimmune encephalomyelitis. Brain2004; 127: 1313–1331.
44.
JonesMVNguyenTTDeboyCA. Behavioral and pathological outcomes in MOG 35-55 experimental autoimmune encephalomyelitis. J Neuroimmunol2008; 199: 83–93.
45.
ColesAJCompstonDASelmajKW. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med2008; 359: 1786–1801.
46.
ZhangJZhangASunYCaoXZhangN. Treatment with immunosuppressants FTY720 and tacrolimus promotes functional recovery after spinal cord injury in rats. Tohoku J Exp Med2009; 219: 295–302.
47.
MironVELudwinSKDarlingtonPJ. Fingolimod (FTY720) enhances remyelination following demyelination of organotypic cerebellar slices. Am J Pathol2010; 176: 2682–2694.
48.
MagliozziRHowellOWReevesC. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol2010; 68: 477–493.
49.
MagliozziRHowellOVoraA. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain2007; 130: 1089–1104.
50.
VesterinenHMSenaESffrench-ConstantCWilliamsAChandranSMacleodMR. Improving the translational hit of experimental treatments in multiple sclerosis. Mult Scler2010; 16: 1044–1055.
